JP4782365B2 - ウイルス感染症と癌細胞を二重ターゲッティングする組成物及び方法 - Google Patents

ウイルス感染症と癌細胞を二重ターゲッティングする組成物及び方法 Download PDF

Info

Publication number
JP4782365B2
JP4782365B2 JP2002584819A JP2002584819A JP4782365B2 JP 4782365 B2 JP4782365 B2 JP 4782365B2 JP 2002584819 A JP2002584819 A JP 2002584819A JP 2002584819 A JP2002584819 A JP 2002584819A JP 4782365 B2 JP4782365 B2 JP 4782365B2
Authority
JP
Japan
Prior art keywords
azt
pharmaceutical composition
compound
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002584819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505499A (ja
JP2005505499A5 (enExample
Inventor
エス． クセラ，ルイス
エー． フレミング，ロナルド
エス． イシャク，カリッド
エル． クセラ，グレゴリー
エル． モリス−ナトシュク，スーザン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University
Original Assignee
Wake Forest University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University filed Critical Wake Forest University
Publication of JP2005505499A publication Critical patent/JP2005505499A/ja
Publication of JP2005505499A5 publication Critical patent/JP2005505499A5/ja
Application granted granted Critical
Publication of JP4782365B2 publication Critical patent/JP4782365B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002584819A 2001-04-27 2002-04-26 ウイルス感染症と癌細胞を二重ターゲッティングする組成物及び方法 Expired - Fee Related JP4782365B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/844,201 US7026469B2 (en) 2000-10-19 2001-04-27 Compositions and methods of double-targeting virus infections and cancer cells
US09/844,201 2001-04-27
PCT/US2002/013338 WO2002087465A2 (en) 2001-04-27 2002-04-26 Compositions and methods of double-targeting virus infections and cancer cells

Publications (3)

Publication Number Publication Date
JP2005505499A JP2005505499A (ja) 2005-02-24
JP2005505499A5 JP2005505499A5 (enExample) 2006-01-05
JP4782365B2 true JP4782365B2 (ja) 2011-09-28

Family

ID=25292094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002584819A Expired - Fee Related JP4782365B2 (ja) 2001-04-27 2002-04-26 ウイルス感染症と癌細胞を二重ターゲッティングする組成物及び方法

Country Status (6)

Country Link
US (3) US7026469B2 (enExample)
EP (1) EP1389970A4 (enExample)
JP (1) JP4782365B2 (enExample)
AU (1) AU2002252731A1 (enExample)
CA (1) CA2445565C (enExample)
WO (1) WO2002087465A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460082A1 (en) * 2003-03-19 2004-09-22 Heidelberg Pharma Holding GmbH Phospholipid esters of clofarabine derivatives
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
LT2574341T (lt) 2004-03-29 2017-09-11 University Of South Florida Navikų ir vėžio efektyvus gydymas triciribino fosfatu
US8101745B2 (en) 2004-12-16 2012-01-24 The Regents Of The University Of California Lung-targeted drugs
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
EP1865967A4 (en) * 2005-04-08 2011-02-09 Chimerix Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
EP2012799B1 (en) * 2006-05-03 2016-08-24 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
US20080249066A1 (en) * 2007-03-23 2008-10-09 Ardea Biosciences, Inc. Antiviral compounds and compositions
WO2009049089A1 (en) 2007-10-09 2009-04-16 Washington University In St. Louis Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
US9446150B2 (en) 2007-10-09 2016-09-20 Washington University Particles for imaging
EP3085377A1 (en) * 2008-01-25 2016-10-26 Chimerix, Inc. Methods of treating viral infections
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
EP2826369A3 (en) * 2008-11-06 2015-03-18 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011084700A1 (en) 2009-12-17 2011-07-14 The Washington University Antithrombotic nanoparticle
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
HUE032860T2 (en) 2010-02-12 2017-11-28 Chimerix Inc A method for treating a virus infection
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
US9192680B2 (en) 2010-06-01 2015-11-24 Aposense Ltd. Pharmaceutical compounds
US8530444B2 (en) * 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
SI2970346T1 (sl) 2013-03-15 2018-12-31 The Regents Of The University Of California Aciklični diestri nukleozid fosfonata
PT3194411T (pt) 2014-09-15 2022-06-06 Univ California Análogos de nucleótidos
CA2968790A1 (en) 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
WO2024020127A1 (en) 2022-07-21 2024-01-25 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2108765A (en) * 1938-02-15 Preserving and disinfecting media
DE279249C (enExample)
US2087132A (en) * 1933-04-13 1937-07-13 Alba Pharmaceutical Company In Quaternary ammonium compounds
US2086585A (en) * 1933-04-13 1937-07-13 Alba Pharmaceutical Company In Quaternary ammonium compounds
US2209383A (en) * 1938-03-05 1940-07-30 Rohm & Haas Process of waterproofing fabrics
US2445393A (en) * 1944-03-08 1948-07-20 Rhone Poulenc Sa New amino-derivatives of dioxa-cyclopentane
US2439969A (en) * 1944-04-17 1948-04-20 Rhone Poulenc Sa Amino-dioxacyclopentanes
US2513747A (en) * 1945-10-04 1950-07-04 Ciba Ltd Cyclic amino-acetals
US2606909A (en) * 1947-08-01 1952-08-12 Univ Michigan Basic dioxolanes
US2689790A (en) * 1951-09-26 1954-09-21 Monsanto Chemicals Nitrogenous compound herbicides
NL189533C (nl) * 1953-07-29 Ates Componenti Elettron Werkwijze voor het aanbrengen van een kunststofhouder met warmte-afvoer rond een geintegreerde schakeling, alsmede combinatie van een matrijs en een warmte-afvoerelement voor gebruik bij deze werkwijze.
US3054678A (en) * 1958-04-16 1962-09-18 Michener Harold David Preservation process with quaternary ammonium compounds
DE1619043B2 (de) 1967-04-07 1977-11-03 Hoechst Ag, 6000 Frankfurt Mittel zum weichmachen von textilien und gleichzeitigem vermitteln einer guten saugfaehigkeit
US4119714A (en) * 1970-02-27 1978-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens
DE2033359C3 (de) * 1970-07-06 1980-02-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Acylpropandiol-(l,3)-phosphorsäuremono-cholinester und Verfahren zu deren Herstellung
JPS49100224U (enExample) 1972-12-19 1974-08-29
JPS49100224A (enExample) 1973-01-29 1974-09-21
US4093714A (en) * 1974-03-15 1978-06-06 Icn Pharmaceuticals, Inc. 9β-D-Arabinofuranosylpurine nucleotides and method of use
US4159988A (en) * 1974-08-06 1979-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic phospholipids, a process for their manufacture and their use
FR2356425A1 (fr) * 1976-07-01 1978-01-27 Roussel Uclaf Application a titre de medicaments de derives organiques de la montmorillonite
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
DE2820893C2 (de) * 1978-05-12 1986-02-20 A. Nattermann & Cie GmbH, 5000 Köln Strukturanaloga von natürlichen Phospholipiden und Verfahren zur Herstellung dieser Verbindungen
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4444766A (en) * 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
JPS5772914A (en) * 1980-10-22 1982-05-07 Takeda Chem Ind Ltd Antitumor agent
US4471113A (en) * 1982-02-03 1984-09-11 The United States Of America As Represented By The Department Of Energy Prodrugs based on phospholipid-nucleoside conjugates
EP0094586A3 (en) 1982-05-13 1984-06-06 Ono Pharmaceutical Co., Ltd. Glycerol derivatives, process for preparing same and pharmaceutical composition containing same
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
JPS5988447A (ja) 1982-11-11 1984-05-22 Ono Pharmaceut Co Ltd グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
JPS60105650A (ja) 1983-11-14 1985-06-11 Ono Pharmaceut Co Ltd グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤
US4540521A (en) * 1984-01-16 1985-09-10 National Distillers And Chemical Corporation Liquid quaternary ammonium antistatic compositions
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4797479A (en) * 1985-04-15 1989-01-10 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
JPS61238793A (ja) 1985-04-17 1986-10-24 Toyo Jozo Co Ltd 新規リン脂質誘導体
US4619917A (en) * 1985-07-18 1986-10-28 Sandoz Pharm. Corp. Substituted 2-furanyl- or 5-oxo-2-furanyl methoxy phosphoryl alkyl cyclimmonium salts
CA1280369C (en) * 1985-12-04 1991-02-19 Hansjorg Eibl Pharmaceutical with anti-tumor effect
US4841039A (en) * 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
DE3619748A1 (de) 1986-06-12 1987-12-17 Merz & Co Gmbh & Co Antimikrobielle mittel
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
EP0262876B1 (en) * 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JP2598643B2 (ja) 1987-07-24 1997-04-09 わかもと製薬株式会社 抗アレルギー剤
DE3726945A1 (de) 1987-08-13 1989-02-23 Dietl Hans L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel
US4894389A (en) 1987-10-02 1990-01-16 Merrell Dow Pharmaceuticals Inc. Novel aminoalkyl-substituted heterocyclic sulfur compounds
US4997761A (en) * 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
US4797497A (en) 1988-02-25 1989-01-10 Amoco Corporation Trimellitic anhydride purification process
EP0335396A1 (en) 1988-04-01 1989-10-04 MAGIS FARMACEUTICI S.p.A. Glycero-phosphoric and -diphosphoric acids derivatives of L-carnitine or L-carnitine esters
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
EP0348859A1 (en) 1988-07-01 1990-01-03 MAGIS FARMACEUTICI S.p.A. 1,2-di-O-acyl glycero(DI)phosphate of L-carnitine and its derivatives, a process for their preparation and pharmaceutical formulations which contain them
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GB8827337D0 (en) 1988-11-23 1988-12-29 Medical Res Council Nucleoside analogues
DD279249A1 (de) 1989-01-01 1990-05-30 Akad Wissenschaften Ddr Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diphosphat-1,2-di-o-alkylglycerolen und deren salzen
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
FI902821A7 (fi) 1989-06-12 1990-12-13 Res Foundation For Mental Hygiene Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE3929217A1 (de) 1989-09-02 1991-03-07 Boehringer Mannheim Gmbh Verwendung von phospholipid-derivaten als antivirale arzneimittel und neue phospholipide
DE3934820A1 (de) 1989-10-19 1991-04-25 Boehringer Mannheim Gmbh Verwendung von lecithin-analoga als antivirale arzneimittel und neue derivate
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB2239243B (en) 1989-12-22 1993-05-12 Scras Glycerol derivatives
DE3942933A1 (de) 1989-12-23 1991-06-27 Boehringer Mannheim Gmbh Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DE4010228A1 (de) 1990-03-30 1991-10-02 Werner E G Prof Dr Mueller Verfahren zur herstellung eines mittels gegen virale infektionen, vorzugsweise gegen aids
US5134394A (en) * 1990-04-12 1992-07-28 Beadle Leigh P Light aircraft navigation apparatus
JPH05507279A (ja) 1990-05-29 1993-10-21 ネクススター・ファーマシューティカルズ・インコーポレイテッド グリセロールジ―およびトリホスフェート誘導体の合成
ATE137242T1 (de) 1990-06-15 1996-05-15 Univ Wake Forest Kovalente-ther lipidnukleosid-konjugate
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5563257A (en) * 1990-08-20 1996-10-08 Boehringer Mannheim Gmbh Phospholipid derivatives of nucleosides
TW207544B (enExample) * 1990-08-20 1993-06-11 Boehringer Mannheim Gmbh
JPH06504429A (ja) 1990-10-09 1994-05-26 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド ウイルス複製の阻害
DE4111730A1 (de) 1991-04-10 1992-10-15 Knoll Ag Neue cytarabin-derivate, ihre herstellung und verwendung
WO1993000910A1 (en) 1991-07-12 1993-01-21 Vical, Inc. Antiviral liponucleosides: treatment of hepatitis b
ES2153365T3 (es) 1991-10-28 2001-03-01 Dennis L Fost Composiciones fosfolipidas antimicrobianas.
DE4204032A1 (de) 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
DE4204031A1 (de) 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US6602861B1 (en) 1992-04-16 2003-08-05 Research Corporation Technologies, Inc. Acylated phospholipid drugs
US5512671A (en) 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
DE69419244T2 (de) * 1993-02-24 1999-10-14 Wang Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
EP0702556B1 (en) * 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
DE4321978A1 (de) 1993-07-01 1995-01-12 Boehringer Mannheim Gmbh Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
WO1995003056A1 (en) * 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
DE4402492A1 (de) 1994-01-28 1995-08-03 Boehringer Mannheim Gmbh Verfahren zur Herstellung von unsymmetrischen Phosphorsäurediestern
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
ATE395922T1 (de) * 1994-08-29 2008-06-15 Univ Wake Forest Lipid-analoge zur behandlung von viralen infektionen
EP0791056B1 (de) 1994-11-12 2005-03-30 Heidelberg Pharma GmbH Lipidspaltender enzymkomplex
JP3786447B2 (ja) 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
IN183120B (enExample) 1996-10-18 1999-09-11 Vertex Pharma
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6243759B1 (en) * 1998-05-08 2001-06-05 International Business Machines Corporation Method and system for configuring dynamic interfaces
IL131887A0 (en) * 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
JP4213841B2 (ja) 2000-03-23 2009-01-21 大成建設株式会社 仮支承の施工方法

Also Published As

Publication number Publication date
JP2005505499A (ja) 2005-02-24
US20060264397A1 (en) 2006-11-23
US7026469B2 (en) 2006-04-11
EP1389970A4 (en) 2005-07-06
WO2002087465A2 (en) 2002-11-07
CA2445565C (en) 2013-07-09
US7638528B2 (en) 2009-12-29
AU2002252731A1 (en) 2002-11-11
CA2445565A1 (en) 2002-11-07
WO2002087465A3 (en) 2003-12-11
US8138200B2 (en) 2012-03-20
EP1389970A2 (en) 2004-02-25
US20020082242A1 (en) 2002-06-27
US20100184718A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
JP4782365B2 (ja) ウイルス感染症と癌細胞を二重ターゲッティングする組成物及び方法
JP5031162B2 (ja) ウイルス感染を二重ターゲティングおよびガン細胞をターゲティングするための組成物および方法
US6030960A (en) Method of treating hepatitis virus infections
US5744461A (en) Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
CA2149753C (en) Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
RU2157215C2 (ru) Способ лечения инфекций, вызываемых вирусом гепатита в
AU711774B2 (en) Prodrugs of pharmaceuticals with improved bioavailability
US20060223835A1 (en) 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
JPH04501255A (ja) 抗ウィルス性ヌクレオシドの脂質誘導体、リポソームの取込みおよび使用方法
JP2011246469A (ja) Ｂ型肝炎ウイルス活性を持ったヌクレオシド
US7309696B2 (en) Compositions and methods for targeting cancer cells
CN102286047A (zh) 2’-脱氧-2’-氟-4’-三氮唑取代-β-D胞苷类似物、其制备方法及其应用
JPH013197A (ja) 抗ウイルス化合物およびそれを含有する抗ウイルス剤
KR19990064240A (ko) 새로운 면역억제제 및 항바이러스 약제로서의 리피드알코올
EP0791056A2 (de) Lipidspaltendes enzym
Calogeropoulou et al. Synthesis and anti-HIV evaluation of alkyl and alkoxyethyl phosphodiester AZT derivatives
Charvet et al. Synthesis and antiviral activity of new carbonylphosphonate 2′, 3′-dideoxy-3′-thiacytidine conjugates
RU2237479C2 (ru) Нуклеозиды, обладающие активностью против вируса гепатита в
Chen et al. Glycoconjugates of adefovir and tenofovir as asialoglycoprotein-mediated Anti-HBV prodrugs with enhanced liver targeting

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110607

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110707

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140715

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees